Literature DB >> 23608446

Advances in therapy for melanoma brain metastases.

Jaclyn C Flanigan1, Lucia B Jilaveanu, Veronica L Chiang, Harriet M Kluger.   

Abstract

Melanoma cells frequently metastasize to the brain, and approximately 50% of patients with metastatic melanoma develop intracranial disease. Historically, central nervous system dissemination has portended a very poor prognosis. Recent advances in systemic therapies for melanoma, supported by improved local therapy control of brain lesions, have resulted in better median survival for these patients. We review current local and systemic approaches for patients with melanoma brain metastases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23608446     DOI: 10.1016/j.clindermatol.2012.08.008

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  21 in total

1.  Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.

Authors:  Daniel K Martin; Ortrud Uckermann; Aiko Bertram; Corina Liebner; Sandy Hendruschk; Kerim Hakan Sitoci-Ficici; Gabriele Schackert; Edith M Lord; Achim Temme; Matthias Kirsch
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

2.  PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Authors:  Lucia B Jilaveanu; Fabio Parisi; Meaghan L Barr; Christopher R Zito; William Cruz-Munoz; Robert S Kerbel; David L Rimm; Marcus W Bosenberg; Ruth Halaban; Yuval Kluger; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  [Cerebral MR imaging of malignant melanoma].

Authors:  M Breckwoldt; M Bendszus
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

4.  Imaging biomarkers for brain metastases: more than meets the eye.

Authors:  Sanjay Aneja; Antonio Omuro
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

5.  Melanoma brain metastasis is independent of lactate dehydrogenase A expression.

Authors:  Terje Sundstrøm; Heidi Espedal; Patrick N Harter; Kristine Eldevik Fasmer; Kai Ove Skaftnesmo; Sindre Horn; Erlend Hodneland; Michel Mittelbronn; Benjamin Weide; Rudi Beschorner; Benjamin Bender; Cecilie Brekke Rygh; Morten Lund-Johansen; Rolf Bjerkvig; Frits Thorsen
Journal:  Neuro Oncol       Date:  2015-03-19       Impact factor: 12.300

6.  A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.

Authors:  Doug Hanniford; Judy Zhong; Lisa Koetz; Avital Gaziel-Sovran; Daniel J Lackaye; Shulian Shang; Anna Pavlick; Richard Shapiro; Russell Berman; Farbod Darvishian; Yongzhao Shao; Iman Osman; Eva Hernando
Journal:  Clin Cancer Res       Date:  2015-06-18       Impact factor: 12.531

7.  Clinical trials in melanoma patients with brain metastases.

Authors:  Melinda L Yushak; Veronica L Chiang; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2015-08-20       Impact factor: 4.693

Review 8.  The Treatment of Melanoma Brain Metastases.

Authors:  Nour Kibbi; Harriet Kluger
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 9.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

10.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.